Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-37724 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Phospho-NFkB p65 (Thr435) Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- A suggested positive control for Western blot is Hela cells; suggested positive control for IHC is human breast carcinoma; suggested positive control for ICC/IF is Hela cells.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 1 mg/mL
- Storage
- -20°C
Submitted references A CRHR1 antagonist prevents synaptic loss and memory deficits in a trauma-induced delirium-like syndrome.
Cursano S, Battaglia CR, Urrutia-Ruiz C, Grabrucker S, Schön M, Bockmann J, Braumüller S, Radermacher P, Roselli F, Huber-Lang M, Boeckers TM
Molecular psychiatry 2021 Aug;26(8):3778-3794
Molecular psychiatry 2021 Aug;26(8):3778-3794
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of extracts from Hela cells, untreated or treated with TNF-alpha and CA, using NF-kappa-B-p65 (pThr435) polyclonal antibody (Product # PA5-37724).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunocytochemical analysis of Phospho-NFkB p65 (Thr435) in methanol-fixed Hela cells, using Phospho-NFkB p65 (Thr435) Polyclonal Antibody (Product # PA5-37724)(Red).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of Phospho-NFkB p65 (Thr435) in paraffin-embedded Human breast carcinoma tissue using Phospho-NFkB p65 (Thr435) Polyclonal Antibody (Product # PA5-37724).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 3 Loss of excitatory synapses in hippocampal cell culture is CRH/BDNF/NF-kappaB-dependent. a IHC for Shank2 (green), Vglut1 (red), MAP2 (magenta) (scale bar = 5 um), western blot analysis for all different treatment regimens (CRH; the CRHR1 blocker NBI30775; the corticosterone receptor blocker RU38486; and BDNF) and the relative quantification. b IHC for Shank2 (green), Vglut1 (red), MAP2 (magenta) and CRHR1 (white) with colocalization and trilocalization analysis (scale bar = 5 um). c IHC for phospho-NF-kappaB p65 (green, scale bar = 5 mum) and the relative quantification of the signal within the nuclear compartment. d IHC for phospho-IKB-alpha and the relative quantification of the signal within the cytosolic compartment. e IHC for and compartment analysis of p65. f IHC (left panel) for Shank2 (green), Vglut1 (red), MAP2 (magenta) (scale bar = 5 um), WB of BDNF (right panel) for all different treatment regimens blocking the NF-kappaB pathway (JSH (the translocation blocker JSH- 23); SC (the IKK-beta inhibitor SC-514); and LAC (the NF-kappaB activation blocker lactacystin)) and the relative quantification. g IHC for ATG5, immunoblot analysis of h BCN-1, i LC3, and j Lamp-2 and the relative quantification normalized to beta-actin. k TEM of acquired synapses after 15 min of CRH treatment (arrows indicate membrane-associated vesicles (scale bar = 0.5 um)) and the relative quantification of docked vesicles and multivesicular bodies (MVBs)/synapses (a two-tailed unpaired T -